QA teams manually review 200–500 pages per batch record line by line, creating 10–20 day backlogs that hold finished product in quarantine. Leucine MES changes this: Cortex AI pre-reviews every record before a human touches it, flags only what needs attention, and enables same-day batch release. At Valent BioSciences, batch review dropped from 20 days to 1 day with 2,700 person-hours saved annually.
Key Highlights
Regulatory Context
The batch record was revised repeatedly by Production to fix missing times and signatures — without QA knowledge or approval. Correction forms were found in the Supervisor's office and discard bins. The Quality Unit lacked visibility to detect these changes.
Subsequent batches were manufactured before QA review of the prior batch record was complete. No system prevented production from continuing without review signoff.
Labels recording visual inspection results during media fills were discarded after transcription into the batch record. The SOP required neither retention of source labels nor second-person verification of the transfer.
CCTV revealed 7 to 167 aseptic filling interventions per batch going unrecorded. Cleaning records documented activities that never occurred. The review process had no mechanism to detect these fabrications.
Batches were released before deviation investigations were complete. Impact assessments lacked supporting data. The Quality Unit did not have access to all relevant information at the time of the release decision.
Instead of opening deviations for critical alarms and environmental excursions, impact assessments were filed with individual batches without tracking or trending. Over 1,200 forms across 2024–2025 were never aggregated or evaluated for systemic root causes.
The Problem
Batch Review in Leucine MES
Before a human reviewer opens the record, Cortex AI has already verified every CPP against specification, confirmed material reconciliation, and flagged deviations. The reviewer inherits a pre-reviewed record, not a blank document.
The reviewer sees a focused exception report: out-of-spec parameters, unresolved deviations, missing verifications. Compliant steps are acknowledged efficiently. QA time goes to judgement calls, not routine confirmation.
Every deviation detected during production is automatically linked to the batch record with its investigation status and CAPA reference. The reviewer sees: deviation → root cause → CAPA → resolution in one view.
Multiple reviewers — production supervisor, QA reviewer, QP — review simultaneously instead of sequentially. Digital routing eliminates physical handoff. All comments and decisions converge in one audit trail.
The QP sees a release dashboard: all CPPs verified ✓, all deviations resolved ✓, all materials reconciled ✓. One electronic signature to release the batch — with a complete audit trail backing every checkmark.
The Solution
Addressing both the review bottleneck that holds product in quarantine and the compliance gaps that FDA finds in batch disposition processes.
Cortex AI pre-reviews the complete batch record. QA reviewers engage only with flagged exceptions. The Quality Unit maintains full oversight with a sealed audit trail.
Review-by-exception works because the batch record is built correctly during execution. Guided workflows and instrument integration mean the record arrives at QA with 95% of data already verified.
LeucineOS analyses structured batch data across your network, surfacing patterns invisible during single-batch review — yield drift, recurring anomalies, and systemic deviation trends.
Monitor how FDA cites batch review failures across the industry. Understand which disposition deficiencies draw 483s so your team knows exactly what inspectors expect.
Results
Real results from manufacturers who replaced manual batch review with AI-powered review-by-exception.
Next Step
Stop losing weeks to batch review backlogs. Leucine MES pre-reviews every record with AI, surfaces only what needs your judgement, and releases batches the same day.
Get Started